Radioimmunotherapy

Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

Also Known As:

Networked: 1663 relevant articles (246 outcomes, 293 trials/studies)

Relationship Network

Therapy Context: Research Results

Experts

1.	Goldenberg, David M: 66 articles (12/2015 - 01/2002)
2.	Press, Oliver W: 41 articles (11/2015 - 05/2002)
3.	Boerman, Otto C: 35 articles (12/2015 - 03/2003)
4.	Sharkey, Robert M: 35 articles (12/2015 - 05/2002)
5.	Oyen, Wim J G: 32 articles (10/2014 - 03/2003)
6.	Brechbiel, Martin W: 30 articles (01/2015 - 04/2002)
7.	Pagel, John M: 26 articles (11/2015 - 03/2003)
8.	Barbet, Jacques: 25 articles (01/2015 - 10/2005)
9.	Dadachova, Ekaterina: 25 articles (12/2014 - 04/2004)
10.	Witzig, Thomas E: 23 articles (09/2015 - 02/2002)

Related Diseases

1.	Neoplasms (Cancer) 12/01/2011 - "The best antitumor activity, with more than 50% of treated animals cured, was achieved with 2 locoregional treatments of intraperitoneally growing tumors on days 2 and 9. These results suggest that radioimmunotherapy with (131)I-AFRA-DFM5.3 is feasible and leads to significantly prolonged survival. " 04/01/1999 - "However, as observed in other tumor types, the intratumoral distribution of the antibody is highly heterogeneous, which may limit the efficacy of radioimmunotherapy. " 12/15/1997 - "Nude mice with xenografted human tumors is the most exploited animal model used to elucidate the efficacy of experimental radioimmunolocalization and radioimmunotherapy. " 01/01/2008 - "Using a 2-step, pretargeting method that separates the bivalent anti-CEA antibody targeting of tumor from the delivery of the radioactive peptide that is captured by the second Fab of the tri-Fab construct, an improved method of cancer imaging and therapy has been developed and shows very sensitive and specific targeting of CEA-expressing tumors for either diagnostic imaging, such as with immunoSPECT and immunoPET, or radioimmunotherapy. " 07/01/2014 - "A higher mean tumor-absorbed dose was significantly predictive of improved PFS after (131)I-tositumomab radioimmunotherapy. "
2.	Non-Hodgkin Lymphoma (Lymphosarcoma) 02/01/2006 - "Radioimmunotherapy has proven clinically effective in patients with non-Hodgkin's lymphoma. " 05/01/2004 - "Radioimmunotherapy produces overall response rates of approximately 80% in patients with low-grade lymphomas, and 25% to 30% of patients achieve a complete remission. " 06/01/2004 - "Radioimmunotherapy (RIT) using (131)I-tositumomab has been used successfully to treat relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). " 01/01/2012 - "Upfront radioimmunotherapy represents an effective and safe therapeutic option in cutaneous B-cell non-Hodgkin lymphoma." 11/01/2008 - "Radioimmunotherapy is an effective treatment for non-Hodgkin's lymphoma (NHL). "
3.	Lymphoma (Lymphomas) 06/01/2001 - "Despite low radiation dose rates, radioimmunotherapy (RIT) has proven particularly effective in the treatment of malignancies, such as lymphoma. " 09/01/2003 - "Beta-irradiation used for systemic radioimmunotherapy (RIT) is a promising treatment approach for high-risk leukaemia and lymphoma. " 01/01/2009 - "EL4 lymphoma-bearing mice either were cured at higher doses of radioimmunotherapy alone or lower doses of radioimmunotherapy in synergy with chemotherapy. " 10/01/1999 - "Although more patients need to be evaluated with a longer follow-up period, radioimmunotherapy appears to be an effective and well-tolerated addition to the oncologists' armamentarium for relapsed lymphomas." 02/01/2015 - "Radioimmunotherapy (RIT) is effective treatment for indolent non-Hodgkin lymphomas (NHLs), but response durations are usually limited, especially in aggressive NHL. "
4.	Ovarian Neoplasms (Ovarian Cancer) 09/01/2003 - "[Radioimmunotherapy in patients with ovarian cancer in complete remission after the first line surgery and chemotherapy after second look laparoscopy procedure]." 02/01/1996 - "The low-affinity monoclonal antibody (MAb) chimeric 17-1A(c-17-1A) and the high-affinity MAb mouse 323/A3 (m-323/A3) were used to study the effect of the MAb affinity on the tumour uptake and efficacy of radioimmunotherapy in nude mice bearing subcutaneously the human ovarian cancer xenografts FMa, OVCAR-3 and Ov.Pe" 10/01/2014 - "Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model." 07/01/1997 - "The favorable physical characteristics of 186Re as well as its efficacy when conjugated to a MAb indicate 186Re as an attractive radionuclide in radioimmunotherapy of ovarian cancer patients." 10/01/2014 - "Recent studies have shown that anti-L1CAM radioimmunotherapy (RIT) with (67)Cu- and (177)Lu-labelled internalising monoclonal antibody (mAb) chCE7 was effective in the treatment of human ovarian cancer xenografts. "
5.	B-Cell Lymphoma (Lymphoma, B Cell) 08/01/2014 - "Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data. " 07/01/1997 - "Radioimmunotherapy, with or without stem-cell transplant support, has produced substantial complete remission rates in chemotherapy-resistant B-cell lymphomas. " 03/01/2006 - "Clinical trials suggest that anti- CD20 radioimmunotherapy is superior to total body irradiation in patients undergoing stem cell supported therapy for B-cell lymphoma, and that it is a safe and efficacious modality when used as consolidation therapy following chemotherapy. " 01/01/2003 - "For more than a decade, radioimmunotherapy has shown great promise for the treatment of B-cell lymphoma. " 10/01/1998 - "Radioimmunotherapy (RIT) is a promising treatment approach for B-cell lymphomas. "

Related Drugs and Biologics

1.	Antibodies
2.	Monoclonal Antibodies
3.	ibritumomab tiuxetan (Zevalin)
4.	Carcinoembryonic Antigen
5.	Antigens
6.	rituximab (Mabthera)
7.	Immunoglobulin G (IgG)
8.	Paclitaxel (Taxol)
9.	Radioisotopes (Radionuclides)
10.	Immunoconjugates (Immunoconjugate)

Related Therapies and Procedures

1.	Heterologous Transplantation (Xenotransplantation)
2.	Drug Therapy (Chemotherapy)
3.	Immunotherapy
4.	Transplants (Transplant)
5.	Radiotherapy